DEHP – performance measurement evaluation

DEHP was first assessed by the Government of Canada in 1994, where it was found to be a possible carcinogenic risk to Canadians. Risk management tools [Cosmetic Ingredient Hotlist (2009), the Phthalates Regulations (2011), reporting of DEHP content under the Medical Devices Regulations (2008), and provisions under the Food and Drugs Act (1985)] were established to help reduce DEHP exposures to the general population of Canada in these products.

The performance measurement evaluation concluded that the risk management tools are meeting their intended goals. Biomonitoring data collected from 3 cycles (2007 to 2017) of the Canadian Health Measures Survey (CHMS) shows that Canadians' exposure to DEHP has progressively decreased since risk management tools were implemented.

The evaluation recommends ongoing measurement of DEHP in the CHMS and monitoring of the Phthalates Regulations. Ongoing reporting of DEHP concentrations in medical devices is also recommended.

Complete details on the performance measurement evaluation for DEHP can be found in the Performance Measurement Evaluation for Risk Management of Bis(2-ethylhexyl) phthalate (DEHP), Health Component.

Related information

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: